Clinical trial
CMV Glycoprotein B Vaccine in Allograft Recipients
NCT00299260 · University College, London, Other · Unknown status
Key facts
| NCT number | NCT00299260 |
|---|---|
| Title | CMV Glycoprotein B Vaccine in Allograft Recipients |
| Official title | A Phase II Immunogenicity Trial of Cytomegalovirus Glycoprotein B Vaccine in Allograft Candidate Recipients |
| Lead sponsor | University College, London, Other |
| Collaborators | National Institute of Allergy and Infectious Diseases (NIAID) NIH |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cytomegalovirus Infections |
| Intervention type | Biological, Drug |
| Interventions | CMV gB vaccine, Placebo |
| Enrollment | 140 |
| Start date | Aug 1, 2006 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2011 |
| First posted | Mar 6, 2006 |
| Last update posted | Apr 19, 2010 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: